[1] |
李贺, 郑荣寿, 张思维, 等. 2014年中国女性乳腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2018, 40(3):166-171.
|
[2] |
张馨月, 陈亮, 郑宇. 血清C肽和胰岛素样生长因子结合蛋白3与乳腺癌患者死亡风险相关性分析[J]. 检验医学, 2022, 37(1):36-40.
|
[3] |
张韶彤, 王素贞, 于清溪, 等. 乳腺癌术后远期复发转移患者临床特征分析[J]. 中华肿瘤防治杂志, 2019, 26(6):406-409.
|
[4] |
张密, 董倩. 三阴性乳腺癌免疫治疗的研究进展[J]. 中国肿瘤, 2020, 29(8):614-620.
|
[5] |
WU Y J, LI L X, LIU L, et al. ASH2L-promoted HOXC8 gene expression plays a role in mixed lineage leukemia-rearranged acute leukemia[J]. Onco Targets Ther, 2020, 13:381-387.
DOI
URL
|
[6] |
LIU Z, SHEN F, WANG H, et al. Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients[J]. Cell Cycle, 2020, 19(13):1632-1640.
DOI
PMID
|
[7] |
周戌, 肖敏, 李三荣, 等. 乳腺癌组织中E-cad、Ki-67的表达及其与临床病理特征和腋窝淋巴结转移的相关性[J]. 现代肿瘤医学, 2021, 29(13):2287-2291.
|
[8] |
邓爽, 徐久东, 卢平, 等. FOXJ1及SATB-1蛋白在三阴性乳腺癌组织中的表达及其对预后的影响[J]. 中国临床研究, 2020, 33(5):593-596.
|
[9] |
TSAI P H, CHIEN Y, WANG M L, et al. Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network[J]. Nucleic Acids Res, 2019, 47(19):10115-10133.
DOI
URL
|
[10] |
CHEN Y, LI Z, ZHANG M, et al. Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1):466.
DOI
PMID
|
[11] |
ZENG K, WU Y, WANG C, et al. ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription[J]. Cancer Sci, 2020, 111(6):2062-2077.
DOI
URL
|
[12] |
ROCHA-VIEGAS L, SILBERMINS M, OGARA M F, et al. Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells[J]. Biochim Biophys Acta Gene Regul Mech, 2020, 1863(1):194475.
DOI
URL
|
[13] |
孙超, 孙士莹, 詹磊, 等. ASH2L在上皮性卵巢癌中的表达及其对SKOV-3细胞系增殖的影响[J]. 安徽医科大学学报, 2021, 56(3):445-448.
|
[14] |
LI D, BAI Y, FENG Z, et al. Study of promoter methylation patterns of HOXA2,HOXA5,and HOXA6 and its clinicopathological characteristics in colorectal cancer[J]. Front Oncol, 2019, 9:394.
DOI
URL
|
[15] |
SONG Y P, XIAN P, LUO H, et al. Comprehensive landscape of HOXA2,HOXA9,and HOXA10 as potential biomarkers for predicting progression and prognosis in prostate cancer[J]. J Immunol Res, 2022, 2022:5740971.
|
[16] |
LIU Z, SHEN F, WANG H, et al. Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients[J]. Cell Cycle, 2020, 19(13):1632-1640.
DOI
PMID
|